Molecular Markers in Oral Squamous Cell Carcinoma for Targeted Therapy: A Study of 60 Patients

JAIN, DR.NIKUNJ

doi:https://doi.org/10.55041/ijsmt.v2i4.095

Plagiarism Passed

Peer reviewed

Open Access

MOLECULAR MARKERS IN ORAL SQUAMOUS CELL CARCINOMA FOR TARGETED THERAPY: A STUDY OF 60 PATIENTS

AUTHORS:

DR.NIKUNJ JAIN

Mentor

Affiliation

DOI: 10.55041/ijsmt.v2i4.095

CC BY 4.0 License:

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

DOWNLOAD ARTICLE

REVIEW REPORT

CITE THIS ARTICLE

Abstract

Oral squamous cell carcinoma (OSCC) is a prevalent malignancy with high morbidity and mortality, particularly in India. Molecular markers such as EGFR, p53, Cyclin D1, and HPV-associated p16 play a crucial role in tumor progression, prognosis, and targeted therapy selection. This study evaluates molecular marker expression in 60 OSCC patients from ENT and pathology departments and correlates them with clinical outcomes. Immunohistochemistry (IHC) analysis revealed significant overexpression of EGFR (70%) and p53 (63%) in advanced stages (Stage III–IV), suggesting poor prognosis. p16 positivity was associated with early-stage disease and better prognosis. Targeted therapies directed against these markers show promising therapeutic potential and may improve survival outcomes

Keywords

Article Information

Article Metrics

Article Views

PDF Downloads

HOW TO CITE

References

Ethics and Compliance

✓ All ethical standards met

This article has undergone plagiarism screening and double-blind peer review. Editorial policies have been followed. Authors retain copyright under CC BY-NC 4.0 license. The research complies with ethical standards and institutional guidelines.

Indexed In